Free Trial
NASDAQ:TIL

Instil Bio 8/14/2023 Earnings Report

Instil Bio logo
$14.48 +1.87 (+14.83%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$14.42 -0.07 (-0.45%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Instil Bio EPS Results

Actual EPS
-$2.80
Consensus EPS
-$4.00
Beat/Miss
Beat by +$1.20
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Instil Bio's next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules.

Conference Call Resources

Instil Bio Earnings Headlines

Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Instil Bio: Time To Hop On The Summit Wave?
JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

View Instil Bio Profile

More Earnings Resources from MarketBeat